BioLineRx Enters into $5.6 Million Royalty Monetization Transaction with Soleus Capital
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BioLineRx (BLRX) signed an agreement with Soleus Capital Management and its affiliates to sell future APHEXDA royalties for a one-time $5.6 million payment. Soleus will acquire BioLineRx’s 14.4% royalty interest in future APHEXDA net sales under its license with Ayrmid Pharma. BioLineRx retains rights to potential commercial milestone payments and royalties attributable to periods before closing. The deal is expected to close on or about November 30, 2026.
BioLineRx plans to use the non-dilutive proceeds to support research and development, including GLIX1, and to make a partial loan repayment to BlackRock EMEA Venture and Growth Lending. In connection with that repayment, BioLineRx’s current $4 million minimum cash balance requirement will be eliminated. The GLIX1 Phase 1/2a trial is enrolling the fourth of five planned dosing cohorts.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major point. Forward-looking: it has not happened yet and may not happen.One-time $5.6 million payment from Soleus Capital Management and its affiliates provides non-dilutive funding under the signed agreement 1× market cap
- Moderate point. Forward-looking: it has not happened yet and may not happen.Current $4 million minimum cash balance requirement will be eliminated in connection with the planned partial loan repayment
- Minor point. Forward-looking: it has not happened yet and may not happen.Partial loan repayment to BlackRock EMEA Venture and Growth Lending is a planned use of proceeds
- Minor point. Forward-looking: it has not happened yet and may not happen.GLIX1 clinical development is a planned use of proceeds; the Phase 1/2a trial is enrolling the fourth of five planned dosing cohorts
- Minor pointPotential commercial milestone payments under the Ayrmid Pharma license remain with BioLineRx
- Minor pointRoyalties attributable to periods before closing remain with BioLineRx
Negative
- Major point. Forward-looking: it has not happened yet and may not happen.14.4% royalty interest in future APHEXDA net sales will transfer from BioLineRx to Soleus at closing
- Moderate point. Forward-looking: it has not happened yet and may not happen.Closing remains pending and is expected on or about November 30, 2026
Key Figures
- One-time payment
- $5.6 million
- Payment for BioLineRx's APHEXDA royalty interest
- Royalty interest sold
- 14.4%
- BioLineRx's interest in future APHEXDA net sales
- Royalty interest excluded
- 3.6%
- Original licensor's interest remains outside the transaction
- Minimum cash balance requirement
- currently $4 million
- Requirement under the loan agreement will be eliminated with partial loan repayment
- Expected transaction closing
- on or about November 30, 2026
- Expected closing date
- GLIX1 dosing cohorts
- Fourth of five planned dosing cohorts
- Ongoing Phase 1/2a clinical trial
Historical Context
-
Fourth GLIX1 cohort dosing began, with no significant treatment-emergent adverse events observed.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
cxcr4 antagonist medical
autologous stem cell transplantation medical
pdac medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Transaction provides non-dilutive capital through sale of BioLineRx's portion of future APHEXDA royalties -
- Funds to support clinical development of GLIX1, including ongoing Phase 1/2a clinical trial, which is currently enrolling the fourth of five planned dosing cohorts -
- BioLineRx retains rights to future commercial milestone payments under its existing license agreement with Ayrmid -
Under the terms of the agreement, Soleus will acquire BioLineRx's
"This transaction enables us to immediately unlock the value of our APHEXDA royalty stream and strengthen our financial position while retaining the potential for future commercial milestone payments," said Philip Serlin, Chief Executive Officer of BioLineRx. "Importantly, the non-dilutive capital will provide additional financial flexibility as we continue to advance our lead development asset, GLIX1, through its ongoing Phase 1/2a clinical trial in glioblastoma and other solid tumors. We believe this transaction represents an attractive, non-dilutive financing solution for our company and our shareholders."
"We are pleased to partner with BioLineRx on this transaction, which provides us with an opportunity to participate in the future commercial performance of APHEXDA," said Benjamin Lund, Partner at Soleus Capital. "We believe APHEXDA represents a differentiated treatment option in stem cell mobilization for patients with multiple myeloma, and we look forward to supporting BioLineRx through this innovative financing arrangement."
BioLineRx intends to use the proceeds to support its ongoing research and development activities, including the clinical development of GLIX1, as well as for working capital and general corporate purposes, including a partial loan repayment to BlackRock EMEA Venture and Growth Lending. In connection with the partial loan repayment, the Company's minimum cash balance requirement under the loan agreement (currently
About APHEXDA® (motixafortide)
APHEXDA is a CXCR4 antagonist approved by the
About BioLineRx
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) is a biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The Company's lead development asset is GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other solid tumors, for which a Phase 1/2a clinical trial has been initiated in the first quarter of 2026. GLIX1 is being developed under a collaboration with Hemispherian AS.
The Company's first approved product, APHEXDA® (motixafortide), is indicated in the
Learn more about who we are, what we do, and how we do it at www.biolinerx.com, or on LinkedIn.
About Soleus Capital
Soleus Capital is an investment firm based in Greenwich, CT focused on the innovative areas of life sciences, including biopharmaceuticals, medical technologies, life sciences tools and diagnostics. With approximately
Forward Looking Statement
Various statements in this release concerning BioLineRx's future expectations constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," and "would," and describe opinions about future events. These include statements regarding management's expectations, beliefs and intentions regarding, among other things, the consummation and expected benefits of the royalty monetization transaction with Soleus Capital; BioLine's receipt and intended use of the transaction proceeds; the completion and expected effects of the partial repayment of BioLine's outstanding loan facility, including the elimination of the minimum cash balance requirement; the future commercial performance, market uptake and net sales of APHEXDA; potential future royalty and commercial milestone payments relating to APHEXDA; the ongoing Phase 1/2a clinical trial of GLIX1, including its enrollment, progress and the timing and results of any clinical readout; and BioLineRx's business strategy, financial position and financing requirements. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause BioLineRx's actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: the clinical development, commercialization and market acceptance of GLIX1 and motixafortide including the degree and pace of market uptake of APHEXDA for the mobilization of hematopoietic stem cells for autologous transplantation in multiple myeloma patients; the initiation, timing, progress and results of BioLineRx's preclinical studies, clinical trials and other therapeutic candidate development efforts; BioLineRx's ability to advance GLIX1 and motixafortide into clinical trials or to successfully complete its preclinical studies or clinical trials; whether the clinical trial results for GLIX1 and motixafortide will be predictive of real-world results; BioLineRx's receipt of regulatory approvals for GLIX1 and motixafortide and the timing of other regulatory filings and approvals; whether access to GLIX1 and motixafortide is achieved in a commercially viable manner and whether GLIX1 and motixafortide receive adequate reimbursement from third-party payors; BioLineRx's ability to establish, manage, and maintain corporate collaborations, as well as the ability of BioLineRx's collaborators to execute on their development and commercialization plans; BioLineRx's ability to integrate new therapeutic candidates and new personnel, as well as new collaborations; the interpretation of the properties and characteristics of BioLineRx's therapeutic candidates and of the results obtained with its therapeutic candidates in preclinical studies or clinical trials; the implementation of BioLineRx's business model and strategic plans for its business and therapeutic candidates; the scope of protection that BioLineRx is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; estimates of BioLineRx's expenses, future revenues, capital requirements and its need for and ability to access sufficient additional financing; risks related to changes in healthcare laws, rules and regulations in the United States or elsewhere; competitive companies, technologies and BioLineRx's industry; BioLineRx's ability to maintain the listing of its ADSs on Nasdaq; statements as to the impact of the political and security situation in Israel on BioLineRx's business which may exacerbate the magnitude of the factors discussed above. These and other factors are more fully discussed in the "Risk Factors" section of BioLineRx's most recent annual report on Form 20-F filed with the Securities and Exchange Commission on March 23, 2026. In addition, any forward-looking statements represent BioLineRx's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. BioLineRx does not assume any obligation to update any forward-looking statements unless required by law.
Contacts:
For BioLineRx:
United States
Chuck Padala
LifeSci Advisors, LLC
IR@biolinerx.com
Israel
Moran Meir
LifeSci Advisors, LLC
moran@lifesciadvisors.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/biolinerx-enters-into-5-6-million-royalty-monetization-transaction-with-soleus-capital-302943737.html
SOURCE BioLineRx Ltd.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.